Category: Emerging Medicine
HFpEF Management Update: SGLT2 InhibitorsDecember 12, 2022
New data presented at the European Society of Cardiology Congress in August in Barcelona, went far to strengthen the case for using SGLT2 inhibitors in patients with HFmrEF or HFpEF.
AHA 2022: SPORT Trial Shows OTC Supplements Don’t Beat Statins for Cholesterol-LoweringNovember 22, 2022
Researchers tested 6 widely used dietary supplements often promoted for improving heart health against low-dose statins and placebo.
AHA 2022: Trials of New Agents for Resistant HypertensionNovember 10, 2022
New data presented at the American Heart Association 2022 Scientific Session included 3 trials looking at new drug treatments for resistant hypertension.
Atrial Fibrillation Studies from ESC 2022September 12, 2022
In recognition of Atrial Fibrillation Awareness month, we wanted to highlight a few of the AF-related studies presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain.
ACC 2022: Update on Mavacamten for Obstructive Hypertrophic CardiomyopathyApril 29, 2022
Mavacamten had a big week at the American College of Cardiology 2022 Scientific Sessions, with two positive Late-Breaking Clinical Trial sessions. Mavacamten is an investigational, first-in-class, cardiac-specific myosin inhibitor that reduces the number of available actin-myosin cross-bridges and thus decreases excessive myocardial contractility.
ACC 2022: Novel Gene-Silencing Therapy Cuts Lp(a) by 98%April 11, 2022
Among the top-notch research presented at the American College of Cardiology 2022 Scientific Sessions was a small phase 1 trial that demonstrated big potential for a therapeutic that will lower lipoprotein [Lp(a)] and reduce atherosclerotic risk.
FDA Approves Empagliflozin for HFpEFMarch 3, 2022
FDA Approves Empagliflozin for Heart Failure with Preserved Ejection Fraction. With this latest FDA approval, it’s time to get up to date on the newest treatments for heart failure. K2P is here to help.
How (and Why) to Keep up with Emerging MedicineSeptember 9, 2020
Staying on top of emerging medicine is vital for providing the best care to patients and has multiple benefits for physicians. Staying on top of emerging medicine is vital for providing the best care to patients and has multiple benefits for physicians.
Rethinking Rhythm Control in AF: Sooner Rather than Later?September 8, 2020
One of the several noteworthy trials presented at the virtual ESC Congress was the EAST-AFNET 4NET 4 trial, which was published concurrently in the New England Journal of Medicine.
The Endothelium: A Common Denominator Underlying “Atypical” Manifestations of COVID-19?June 15, 2020
A group of Italian researchers recently hypothesized that it is actually the endothelium that is being targeted by the COVID-19 virus.